# Tesamorelin FAQ: Common Questions, Answered and Cited

> Tesamorelin FAQ: is it a growth hormone, is it FDA approved, what are the side effects, does it affect blood sugar, who should avoid it. Direct, cited answers from the research record.

The questions readers actually ask about tesamorelin — answered directly, cited to the studies, and scoped honestly to what the literature shows.

## What is tesamorelin?

A synthetic 44-amino-acid analogue of human growth-hormone-releasing hormone, GHRH(1-44), carrying an N-terminal trans-3-hexenoyl group that resists DPP-IV cleavage [1]. It stimulates the body's own pulsatile growth hormone and raises IGF-1. It is FDA-approved only to reduce excess abdominal visceral fat in HIV-associated lipodystrophy [5].

## What does tesamorelin do?

It binds the GHRH receptor on pituitary somatotrophs and stimulates synthesis and pulsatile secretion of endogenous growth hormone, which raises hepatic IGF-1; together these promote lipolysis preferentially in visceral fat [1]. In trials this selectively reduced visceral abdominal fat in HIV patients by 15.2% [1].

## How does tesamorelin work?

It is a GHRH-receptor agonist: activation triggers the Gs/adenylyl-cyclase/cAMP/PKA cascade in somatotrophs, driving GH gene transcription and pulsatile GH release [1]. GH then stimulates hepatic IGF-1, and the GH/IGF-1 axis activates hormone-sensitive lipase to break down visceral fat. The trans-3-hexenoyl N-terminal modification blocks DPP-IV, extending activity versus native GHRH [1].

## Is Tesamorelin a Growth Hormone?

No. It is not exogenous growth hormone; it is a GHRH analogue that stimulates the pituitary to release the body's own GH in its natural pulsatile rhythm [1]. That upstream mechanism distinguishes its metabolic profile from recombinant GH, which supplies hormone directly [4].

## Is Tesamorelin a Steroid or a Growth Hormone?

Neither. Tesamorelin is not an anabolic steroid, and it is not externally supplied growth hormone. It is a peptide GHRH analogue that prompts the body to release its own GH [1]. Its insulin-sensitivity-sparing profile in healthy men reflects that upstream, rhythm-amplifying mechanism rather than a flat external dose [4].

## Does Tesamorelin Affect Blood Sugar or Diabetes Risk?

GH-axis stimulation can perturb glucose modestly, so monitoring is warranted in dysglycemia. In the 52-week HIV program, glucose changes were not clinically significant [2], and a dedicated 12-week type-2-diabetes RCT found no significant change in fasting glucose, HbA1c, or insulin response versus placebo. In healthy men, insulin-stimulated glucose uptake was unaffected (P=0.61) [4].

## What Are the Side Effects of Tesamorelin?

Trials most commonly reported injection-site reactions plus GH-class effects — arthralgia, fluid retention, headache, and paresthesia [7]. The FDA label warns about stimulating endogenous GH and raising IGF-1, and lists contraindications including active malignancy, hypersensitivity, and pregnancy [5]. LiverTox rates it unlikely to cause clinically apparent liver injury (score E) [5].

## Does Tesamorelin Cause Water Retention?

Fluid retention is a recognized growth-hormone-axis class effect and was reported among tesamorelin trial adverse events, often as peripheral oedema [7][8]. It reflects the GH/IGF-1 mechanism rather than a property unique to the peptide; the dedicated type-2-diabetes trial reported only mild adverse events with no serious events.

## Who Should Not Take Tesamorelin?

The FDA label contraindicates use in anyone with active malignancy (treatment must be complete and the malignancy inactive first), known hypersensitivity to tesamorelin or excipients, and pregnancy (animal organogenesis studies showed hydrocephaly in offspring) [5]. These are label contraindications for the approved product, summarized here as research information, not personal medical advice.

## How much fat can I lose on tesamorelin?

In the studied HIV populations, the pivotal RCT reported about a 15.2% visceral-fat reduction at 26 weeks and roughly 18% sustained over 52 weeks [1][2]; a 2026 meta-analysis of five RCTs pooled a VAT reduction of about 27.71 cm2 [12]. These are group averages in trial participants, not a personal target or a recommendation.

## Does tesamorelin work for fat loss in non-HIV users?

The pivotal efficacy RCTs were all conducted in HIV-positive adults on antiretroviral therapy [1][2]. Non-HIV human data are limited to a mechanistic study in healthy men (GH and IGF-1 rose; insulin sensitivity preserved) [4] and a cognition trial; no large general-population fat-loss RCT has been completed. Any non-HIV use is off-label and investigational.

## What is the half-life of tesamorelin?

Plasma exposure is short. Population PK modeling reported apparent clearance of about 1,060 L/h [1]; secondary sources (FDA label, Mayo Clinic) describe a terminal half-life on the order of ~26-38 minutes. Despite rapid clearance, downstream IGF-1 elevation persists across the dosing interval, which supports once-daily administration [1].

## How long does tesamorelin stay in your system?

The peptide itself clears rapidly from plasma (terminal half-life ~26-38 minutes per secondary sources), but its downstream effect — elevated IGF-1 — persists across the day [1]. Population PK found the absorbed fraction rose about 13% by day 14 versus day 1, with no clinically relevant demographic covariates [1].

## Is tesamorelin FDA approved?

Yes, but narrowly. Tesamorelin was FDA-approved in 2010 (NDA 022505) to reduce excess abdominal visceral fat in HIV-infected adults with lipodystrophy [5]. There is no FDA indication outside HIV-associated lipodystrophy; every other use is off-label. It is also prohibited in sport under WADA category S2.

---

The tesamorelin literature laid out as a study syllabus — the GHRH-analogue peptide and its visceral-fat trials walked step by connected step, each figure tagged to its study and the FDA-approved-for-HIV-lipodystrophy-only scope posted at the head of the path; a research curriculum, not a clinic, a vendor, or a prescription.